Sartorius joins the DAX Blue Chip Index


GTTINGEN, Germany, September 4, 2021 / PRNewswire / РLife sciences group Sartorius will be listed in the German DAX blue chip index. After the market closes September 17, 2021, Sartorius preferred shares will be included in the DAX calculation, as Deutsche B̦rse announced on Friday evening. In addition, Sartorius preferred shares will continue to be listed on TecDAX, the leading index of German technology stocks.

“Sartorius has been very dynamic. Based on customer focus, innovation and profitable and sustainable growth, our company creates value for customers, employees and investors, and we would like to thank all of these stakeholders for their many years of service. confidence. Today we are delighted that the performance of our stocks led to their inclusion in the DAX. At the same time, we are aware that the development of stock prices also depends on market factors that we cannot influence. Membership in DAX shows the growing importance of the biotechnology and life sciences sectors and puts Sartorius even more in the public eye. Last but not least, it gives us greater visibility as an employer ”, declared Joachim kreuzburg, Chairman of the Management Board and CEO of Sartorius.

Deutsche Börse had decided on various rule changes for its indices at the end of 2020 and announced that it would expand the DAX index from 30 to 40 members. Following this reform, the DAX will include the 40 largest companies listed on Deutsche Börse according to their free float market capitalization. As a result, after deducting Sartorius shares which are not freely tradable, approximately 72% of its preferred shares will be included in this index, while ordinary shares will not be included in the calculation. Thus, approximately one third of the total market capitalization of Sartorius will be taken into account in determining membership in the DAX.

This press release contains forward-looking statements concerning the future development of the Sartorius group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no responsibility for updating these statements in light of new information or future events. This is a translation of the original German press release. Sartorius assumes no responsibility for the accuracy of this translation. The original German press release is the legally binding version.

A profile of Sartorius
The Sartorius Group is a leading international partner in life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Laboratory Products and Services division focuses on the needs of laboratories performing research and quality controls in pharmaceutical and biopharmaceutical companies and those of academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focused on single-use solutions, helps customers manufacture biotechnology drugs and vaccines safely and efficiently. The Group is experiencing double-digit annual growth on average and is regularly expanding its portfolio through acquisitions of complementary technologies. In fiscal year 2020, the company achieved sales of approximately 2.34 billion euros. At the end of 2020, nearly 11,000 people were employed at the approximately 60 manufacturing and sales sites of the Group, serving customers around the world.

Follow Sartorius on Twitter and on LinkedIn.

Timo lindemann
Business communication
+49 (0) 551.308.4724
[email protected]

Logo –

View original content:

SOURCE Sartorius SA


About Author

Leave A Reply